Ryan C W, Herndon J, Vogelzang N J
Department of Medicine, University of Chicago, IL 60637, USA.
Chest. 1998 Jan;113(1 Suppl):66S-73S. doi: 10.1378/chest.113.1_supplement.66s.
Treatment of malignant pleural mesothelioma continues to be frustrating regardless of the modality employed. Numerous trials of chemotherapeutic agents have been performed, but until recently, these studies were small and subject to inaccuracies of disease measurement. To our knowledge, no chemotherapeutic regimen has emerged as a standard of care. A review of the literature reveals that small activity against this disease has been shown by the anthracyclines, platinum compounds, and alkylating agents, whereas higher activity has been reported with the antimetabolites. The plant alkaloids have not demonstrated any activity against mesothelioma. Dose-escalated chemotherapeutic regimens may offer an advantage, whereas combination chemotherapy has not shown any benefit over single-agent therapy. Favorable responses have been reported with the administration of intrapleural biological response modifiers. Further trials and the investigation of new agents in the treatment of this disease are necessary.
无论采用何种治疗方式，恶性胸膜间皮瘤的治疗仍然令人沮丧。已经进行了许多化疗药物试验，但直到最近，这些研究规模较小，且疾病测量存在不准确之处。据我们所知，尚无化疗方案成为标准治疗方法。文献综述显示，蒽环类药物、铂类化合物和烷化剂对这种疾病显示出较小的活性，而抗代谢物则报告有较高活性。植物生物碱尚未显示出对间皮瘤有任何活性。剂量递增的化疗方案可能具有优势，而联合化疗并未显示出比单药治疗有任何益处。胸膜内给予生物反应调节剂已报告有良好反应。有必要进一步开展试验并研究治疗该疾病的新药物。
